*For medical professionals only
Clinical decision making could be simpler
01Hypertension
1.1
Adult (domestic usage)
1.1.1 Indications
Treatment of mild to moderate essential hypertension [1-5].
1.1.2 Dosage
Tablets:
Recommended dose: This product is 80mg, once a day. Dosage is not related to race, age, or sex. It can be taken with a meal or on an empty stomach. It is recommended to take the drug at the same time each day (eg in the morning).
The exact antihypertensive effect can be achieved within 2 weeks of medication, and the maximum effect can be achieved after 4 weeks. When the antihypertensive effect is not satisfied, the daily dose can be increased to 160 mg, or a diuretic can be added. Valsartan can be used in combination with other antihypertensive drugs.
Foreign clinical application data reported that the maximum dose can reach 320mg, once a day [1-5].
1.2
Adult (FDA)
1.2.1 Indications
Valsartan is used to lower blood pressure in adults and children 6 years of age and older with high blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, mainly stroke and myocardial infarction.
These benefits have been demonstrated in numerous controlled trials of antihypertensive drugs, including trials of valsartans. There are no controlled trials showing that valsartan reduces the risk in people with high blood pressure.
Valsartan can be used alone or in combination with other antihypertensive drugs [6-7].
1.2.2 Dosage
Oral solution:
The recommended starting dose of valsartan oral solution is 40 mg or 80 mg twice daily as monotherapy in patients with adequate blood volume. Patients who require greater blood pressure lowering can start with a dose of 80 mg twice daily. Valsartan oral solution can be used in total daily doses over the range of 80 mg-320 mg.
The antihypertensive effect basically appears within 2 weeks, and the maximum blood pressure reduction effect is reached after 4 weeks. If additional antihypertensive effect is required after the initial dose, the total daily dose can be increased to a maximum of 320 mg or a diuretic can be added. Adding a diuretic is more effective than increasing the dose beyond 80 mg.
Elderly patients, patients with mild to moderate renal impairment, and patients with mild to moderate hepatic insufficiency do not need to adjust the initial dose.
Closely monitor patients with severe hepatic or renal impairment.
Valsartan oral solution can be used in combination with other antihypertensive drugs [6].
Tablets:
When used as monotherapy in non-volume-depleted patients, the recommended starting dose of valsartan tablets is 80 mg or 160 mg once daily. Patients requiring greater reductions may start with higher doses. Valsartan tablets are available in doses ranging from 80 mg to 320 mg daily, administered once daily.
The antihypertensive effect basically appears within 2 weeks, and the maximum blood pressure reduction effect is reached after 4 weeks. If additional antihypertensive effect is required after the initial dose, the total daily dose can be increased to a maximum of 320 mg or a diuretic can be added. Adding a diuretic is more effective than increasing the dose beyond 80 mg.
Valsartan tablets can be used in combination with other antihypertensive drugs [7].
02Heart failure
2.1
Adult (FDA)
2.1.1 Overview
Valsartan is used in the treatment of heart failure (NYHA class II-IV) to reduce the risk of hospitalization for heart failure in patients who cannot swallow valsartan tablets. There is no evidence of additional benefit when valsartan is used with appropriate doses of angiotensin-converting enzyme (ACE) inhibitors [6-7].
2.1.2 Dosage
Oral solution, tablet:
The recommended starting dose of valsartan oral solution is 40 mg twice daily. According to the patient’s tolerance, adjust to 80mg and 160mg twice a day. Dosage reduction should be considered when combined with diuretics. The maximum daily dose in clinical trials is 320 mg in divided doses [6-7].
03LV failure or insufficiency after myocardial infarction
3.1
Adult (FDA)
3.1.1 Overview
Valsartan is used to reduce the risk of cardiovascular death in clinically stable patients who are unable to swallow valsartan tablets after myocardial infarction, left ventricular failure or insufficiency [6-7] .
3.1.2 Dosage
Oral solution/tablet:
Valsartan Oral Liquid is started as early as possible within 12 hours of myocardial infarction. The recommended starting dose of valsartan oral solution is 20 mg twice daily.
Patients can be titrated up to 40 mg twice daily over 7 days, and then titrated to a target maintenance dose of 160 mg twice daily as tolerated by the patient.
Consider dose reduction if symptomatic hypotension or renal insufficiency occurs. Valsartan oral solution can be administered concurrently with other standard post-MI therapy, including thrombolytics, aspirin, beta-blockers, and statins [6-7].
References:
[1]Drug information: Instructions for Valsartan Tablets.
[2]Drug information: Valsartan Capsules, approved by Chinese medicine 80mg H20040217; 160mg H20040216; 2018/04/04.
[3]Drug information: Valsartan Capsules, approved by Chinese medicine H20020824; 2015/12/01.
[4]Drug information: valsartan dispersible tablets, approved by Chinese medicine H20080820; 2012/11/13.
[5]Drug information: valsartan dispersible tablets, approved by Chinese medicine H20051350; 2013/04/12.
[6]Product Information:VALSARTAN solution,Novitium Pharma LLC,Updated November 5,2021.
[7]Product Information:VALSARTAN tablet,Lupin Pharmaceuticals,Inc., Updated September 14,2021.
First article: Clinical Decision Assistant
The author of this article: Jie Xiaoyao
Editor in charge: Xiao Dangdang
More evidence-based medication
FollowClinical Pharmacy ChannelView
The medical community strives for the accuracy and reliability of its published content when it is reviewed and approved, but does not make any guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), etc. Any commitments and guarantees, and do not assume any responsibility due to the outdated content, the possible inaccuracy or incompleteness of the cited information. Relevant parties are requested to check separately when adopting or using it as a basis for decision-making.